Adjuvant systemic therapy of gastrointestinal stromal tumors: The Scandinavian Sarcoma Group perspective.
Gastrointestinal stromal tumors (GISTs) have a malignant potential varying from virtually no risk of recurrence (microscopic GISTs) to a high risk. Acquired secondary mutations that interfere with imatinib binding have been identified as a common mechanism for drug resistance and tumor progression i...
| Publicado en: | Acta Orthopaedica (Supplement) Vol. 80; pp. 37 - 44 |
|---|---|
| Autores principales: | , |
| Formato: | tables/charts Journal Article |
| Publicado: |
Medical Journals Sweden AB
Apr2009 Supplement 334
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105399005&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105399005 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 17453690 1WHY jtl: Acta Orthopaedica (Supplement) issn: 17453690 maglogo: N pubinfo: dt: Apr2009 Supplement 334 vid: 80 pid: 59195 pub: Medical Journals Sweden AB artinfo: ui: 105399005 105399005 2010362996 10.1080/17453690610046602 105399005 ppf: 37 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Adjuvant systemic therapy of gastrointestinal stromal tumors: The Scandinavian Sarcoma Group perspective. aug: au: Joensuu H Eriksson M affil: Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; heikki.joensuu@hus.fi sug: subj: Chemotherapy, Adjuvant Scandinavia Gastrointestinal Neoplasms Drug Therapy Disease Progression Drug Resistance Early Intervention Gastrointestinal Neoplasms Complications Gastrointestinal Neoplasms Epidemiology Gastrointestinal Neoplasms Familial and Genetic Gastrointestinal Neoplasms Physiopathology Imatinib Adverse Effects Incidence Mutation Neoplasm Recurrence, Local Risk Factors Patient Selection Practice Patterns Scandinavia Survival Treatment Duration Treatment Outcomes ab: Gastrointestinal stromal tumors (GISTs) have a malignant potential varying from virtually no risk of recurrence (microscopic GISTs) to a high risk. Acquired secondary mutations that interfere with imatinib binding have been identified as a common mechanism for drug resistance and tumor progression in advanced GIST. Patients with advanced GIST but with a small tumor mass have the longest time to disease progression suggesting that the rate of secondary mutations that confer drug resistance may be low when the number of cancer cells is small. Thus, early administration of imatinib in the adjuvant setting might result in a low rate of secondary mutations and might improve survival. The results of the ACOSOG Z9001 trial demonstrated a significantly longer recurrence-free survival among patients treated with adjuvant imatinib as compared to placebo. Although data on influence of adjuvant imatinib on overall survival is lacking, its administration may be warranted to patients who have a high risk of recurrence and death from GIST that likely exceeds the risks related to adjuvant administration of imatinib. Many aspects of adjuvant treatment remain unknown including the overall benefits and harms of adjuvant treatment, optimal selection of patients for treatment, and the duration of adjuvant treatment, which is currently being investigated in the ongoing Scandinavian Sarcoma Group/AIO trial (SSG/AIO XVIII). pubtype: Academic Journal doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|